Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multi-center, 6-week, Sequential Cohort Study Designed to Determine the Safety and Tolerability of Two Dose Ranges of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-affective Disorder

NCT00480571 is registered in ClinicalTrials.gov with BioLineRx, Ltd. as lead sponsor.

NCT NCT00480571
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00480571 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multi-center, 6-week, Sequential Cohort Study Designed to Determine the Safety and Tolerability of Two Dose Ranges of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-affective Disorder
Lead sponsor
BioLineRx, Ltd.
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2007
Completion date
December 31, 2007
Enrollment
90 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

schizoaffective disorder, schizophrenia